The success of Sildenafil initially drove a period of growth for pharma, however recent changes present a complicated outlook for those considering a stake. Off-patent competitors are eroding profits, and continued https://arunlcbd062354.blogpostie.com/62393737/the-blue-pill-and-big-pharma-a-volatile-play